Anti-aging: state of the art

Published on LessWrong, this is one of the more approachable summaries of the field. One exciting point: “Today, there are over 130 longevity biotechnology companies and over 50 anti-aging drugs in clinical trials in humans.” However, a commenter offers this alternative interpretation: “The fact that there are 130 companies working on the problem with only minor laboratory success in the last decade indicates that the marginal returns to new inputs is low.” | learn more